Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: Results of a multicenter analysis

Blood Cancer Journal

Volumn 4, Issue 8, 2014, Pages

  Lu, J ^a   Chen, W ^c   Huo, Y ^d   Huang, X ^a   Hou, J ^b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CANCER STAGING; CHINA; CHROMOSOME 17; CHROMOSOME DELETION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIPLE MYELOMA; PATHOLOGY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; SURVIVAL RATE;

EID: 84906859247     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.55     Document Type: Article

References (16)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.p
2. Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T et al. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol 2012; 158: 91-98.p
3. Jain RV, Mills PK, Parikh-Patel A. Cancer incidence in the south Asian population of California, 1988-2000. J Carcinog 2005; 4: 21.p
4. Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY et al. Racial disparities in incidence and outcome in multiple myeloma: a populationbased study. Blood 2010; 116: 5501-5506.p
5. Wang Q, Wang Y, Ji Z, Chen X, Pan Y, Gao G et al. Risk factors for multiple myeloma: a hospital-based case-control study in Northwest China. Cancer Epidemiol 2012; 36: 439-444.p
6. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.p
7. Geng C, Liu N, Yang G, Liu A, Leng Y, Wang H et al. Retrospective analysis of 264 multiple myeloma patients. Oncol Lett 2013; 5: 707-713.p
8. He J, Yang L, Meng X, Wei G, Wu W, Han X et al. A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma. Am J Med Sci 2013; 345: 88-93.p
9. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.p
10. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489-3495.p
11. Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005; 105: 358-360.p
12. Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011; 25: 906-908.p
13. Chen HF, Wu TQ, Li ZY, Shen HS, Tang JQ, Fu WJ et al. Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance. Oncol Targets Ther 2012; 5: 329-334.p
14. Kim MK, Suh C, Lee DH, Min CK, Kim SJ, Kim K et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol 2011; 22: 411-416.p
15. Hayashi T, Yamaguchi I, Saitoh H, Takagi M, Nonaka Y, Nomura T. Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis. Intern Med 2003; 42: 605-608.p
16. Schmielau J, Teschendorf C, Konig M, Schmiegel W, Graeven U. Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma. Leuk Lymphoma 2005; 46: 567-569.p